Taysha Gene Therapies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 4.75 million. Net loss was USD 117.09 million compared to USD 26.53 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to USD 0.65 a year ago.
For the nine months, sales was USD 11.85 million. Net loss was USD 159.31 million compared to USD 110.94 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 2.79 a year ago. Diluted loss per share from continuing operations was USD 1.88 compared to USD 2.79 a year ago.